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Age-related macular degeneration (AMD), a leading cause of blindness worldwide, is as prevalent 
as cancer in industrialized nations. Most blindness in AMD results from invasion of the retina by 
choroidal neovascularization (CNV). We report that the eosinophil/mast cell chemokine receptor 
CCR3 is specifically expressed in CNV endothelial cells in humans with AMD, and that, despite 
the expression of its ligands eotaxin-1, -2, and -3, neither eosinophils nor mast cells are present in 
human CNV. Genetic or pharmacological targeting of CCR3 or eotaxins inhibited injury-induced 
CNV in mice. CNV suppression by CCR3 blockade was due to direct inhibition of endothelial cell 
proliferation, and was uncoupled from inflammation as it occurred in mice lacking eosinophils or 
mast cells and was independent of macrophage and neutrophil recruitment. CCR3 blockade was 
more effective at reducing CNV than vascular endothelial growth factor-A (VEGF-A) 
neutralization, which is currently in clinical use, and, unlike VEGF-A blockade, not toxic to the 
mouse retina. In vivo imaging with CCR3-targeting quantum dots located spontaneous CNV 
invisible to standard fluorescein angiography in mice before retinal invasion. CCR3 targeting 
might reduce vision loss due to AMD through early detection and therapeutic angioinhibition.
AMD affects 30-50 million people globally, with approximately 90% of severe vision loss 
attributed to CNV1. The worldwide prevalence of CNV is expected to double in the next 
decade due to population aging. Targeting the pro-angiogenic cytokine vascular endothelial 
growth factor (VEGF)-A has been validated in patients with CNV2-4. However, substantial 
improvement of vision occurs only in one-third of patients treated with VEGF-A 
antagonists, and one-sixth of treated patients still progress to legal blindness. Moreover, 
safety concerns with continual blockade of VEGF-A, which is constitutively expressed in 
the normal adult human retina5, are emerging6,7. Thus, treatment strategies based on more 
specific targeting of CNV are desirable. However, no molecular marker specific for human 
CNV has yet been reported.
CCR3 expression restricted to CNV in human eyes
In our studies examining the role of chemokines in angiogenesis, we discovered that CCR3 
(also known as CD193), a chemokine receptor best known for its role in promoting 
eosinophil and mast cell trafficking8, was expressed in human choroidal endothelial cells 
(CECs) only in the context of CNV due to AMD and not in other non-proliferating or 
proliferating choroidal vasculature (Fig. 1). Immunolocalization studies showed that CCR3 
was expressed in CECs of all examined specimens of surgically excised CNV tissue from 
patients with AMD (18/18) who had received no prior treatment for AMD (Fig. 1a, b; 
Supplementary Fig. S1). In contrast, CCR3 was not expressed in CECs in the choroid of any 
patients with early (atrophic) AMD (0/10) or in age-matched patients without AMD (0/10) 
(Fig. 1c, d). CCR3 also was not immunolocalized in surgically excised tissue from patients 
with epiretinal fibrotic membranes (0/6) or in CECs in patients with choroidal melanoma 
(0/8) (Fig. 1e, f). Collectively these data point to a highly specific pattern of expression of 
CCR3 (P = 7×10−14, exact contingency table test) in CECs in neovascular AMD. In 
addition, we identified the expression of the CCR3 ligands eotaxin-1 (CCL11), -2 (CCL24), 
and -3 (CCL26) in all examined specimens of surgically excised CNV tissue from patients 
with AMD who had received no prior treatment for AMD (Fig. 1g-j), suggesting that the 
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eotaxin-CCR3 axis could play a role in this disease state. Interestingly, despite the 
abundance of eotaxins, eosinophils and mast cells were not identified in human CNV 
(Supplementary Fig. S2), consistent with earlier findings9.
CCR3 stimulation promotes CEC migration and proliferation
The best elucidated pathological functions of CCR3 to date have been its role in allergic 
diseases such as asthma10-14 and eosinophilic esophagitis15. There is a single report of its 
direct role in angiogenesis16. Although eosinophils and mast cells have been reported to be 
involved in angiogenesis17,18, such actions are considered minor or isolated. Therefore, we 
studied the effects of CCR3 modulation on angiogenesis in vitro and in vivo. Neutralizing 
anti-CCR3 antibodies inhibited the tube formation of primary human CECs cultured in 
Matrigel in vitro (Fig. 2a). In an experimental model of CNV induced by laser injury in 
wild-type mice19-24, neutralizing anti-CCR3 antibodies reduced the fraction of CECs in 
vivo that was in the proliferative state of the cell cycle (Fig. 2b). Consistent with this finding, 
each of the three eotaxins stimulated human CEC proliferation (Fig. 2c). Cytoskeletal 
rearrangement through polymerization of monomeric actin to microfilamentous F-actin, 
which is essential for eosinophil chemotaxis induced by the eotaxins, is also critical in 
angiogenic migration of endothelial cells. Stimulation of human CECs with any of the three 
eotaxins induced a rapid polymerization of actin molecules (Fig. 2d, e). All three eotaxins 
also activated Rac-1 (Supplementary Fig. S3), a small GTPase that is critical in regulating 
endothelial cell spreading and migration, and promoted human CEC migration in a dose-
dependent fashion (Fig. 2f). Collectively these data demonstrate that CCR3 activation can 
promote multiple steps of angiogenesis. The expression of CCR3 on CECs in vivo is 
confined to CNV tissues; however, in vitro, human CECs responded to CCR3 ligands. This 
might be due to the presence of several CNV-promoting growth factors in the culture 
medium.
CCR3 receptor or ligand antagonism inhibits CNV
We studied the in vivo effects of CCR3 targeting in a mouse model of CNV induced by laser 
injury22 that is the most widely utilized animal model of this disease. A single intraocular 
administration of either CCR3 neutralizing antibodies or a small molecule CCR3 receptor 
antagonist ((S)-Methyl-2-naphthoylamino-3-(4-nitrophenyl)propionate) both suppressed 
laser injury-induced CNV in wild-type mice in a dose-dependent fashion (Fig. 3a-c). CNV 
was also diminished in Ccr3−/− mice25 compared to wild-type mice (Fig. 3d). The 
specificity of pharmacological CCR3 blockade was confirmed by demonstrating that CNV 
was not reduced in Ccr3−/− mice by CCR3 neutralizing antibodies or CCR3 receptor 
antagonist (116±7% and 109±16% of control, respectively; n = 5; P > 0.1). CCL-11 and 
CCL-24, the principal mouse ligands for CCR3, were markedly increased soon after laser 
injury and immunolocalized to the retinal pigmented epithelium (RPE), which is adjacent to 
CECs (Fig. 3e, f). Also, human RPE cells synthesized all three eotaxins (Supplementary Fig. 
S4), implicating these cells, which are abundantly interspersed in CNV9, as a source of 
CCR3 ligands in CNV. Genetic ablation of either Ccl11 (ref. 26) or Ccl24 (ref. 12) reduced 
CNV, while the neovascular response in Ccl11−/− × Ccl24−/− mice12 was suppressed to a 
greater extent than in either of the “single knockout” mice, suggesting cooperation between 
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these two ligands in this system (Fig. 3g). A single intraocular administration of neutralizing 
antibodies against CCL-11 or CCL-24 also suppressed CNV in wild-type mice (Fig. 3h, i), 
validating these CCR3 ligands as anti-angiogenic targets. Together, these data demonstrate 
that CCR3 activation is essential for in vivo angiogenesis in the most widely used preclinical 
model of neovascular AMD.
CCR3-driven angiogenesis uncoupled from inflammation
We sought to determine whether CCR3 targeting reduced CNV solely via anti-angiogenic 
mechanisms or whether anti-inflammatory mechanisms also were involved. Neither 
eosinophils nor mast cells (defined as CCR3hiCD3−CD117intCD49d+ and 
CCR3intCD3−CD117hiCD49d+ cells, respectively) were recruited to the choroid following 
laser injury, as monitored by flow cytometry (Supplementary Fig. S5). Furthermore, the 
CNV response in eosinophil-deficient Δdbl GATA mice11 and mast cell-deficient KitW-v/
KitW-v mice27 was not different from that in wild-type mice (Fig. 3j). In addition, 
intraocular administration of neutralizing anti-CCR3 antibodies reduced CNV in Δdbl 
GATA or KitW-v/KitW-v mice to the same extent as in wild-type mice. Thus, although 
eosinophils and mast cells have been reported to be capable of driving angiogenesis in other 
systems17,18, both cell types are dispensable in the development of experimental CNV. 
Although neutrophil and macrophage infiltration are crucial for the development of 
experimental CNV23,28, CCR3 receptor targeting did not affect recruitment of either 
inflammatory cell type (defined as Gr-1+F4/80− and F4/80+CD11c− cells, respectively) 
(Supplementary Fig. S5). Therefore, the angioinhibitory effect of CCR3 blockade in this 
model is a direct anti-vascular effect and does not appear to involve modulation of cellular 
inflammation. The mechanisms underlying the paucity of eosinophils and mast cells in CNV 
remain to be defined. One potential explanation could be the expression of CXCL9, which 
blocks eotaxin-induced CCR3-mediated eosinophil recruitment29,30, in CNV 
(Supplementary Fig. S6). Other mechanisms influencing adhesion or mobilization of these 
leukocytes also might be operative.
CNV bioimaging by CCR3 targeting
Because invasion of the retina by CNV results in morphological and functional disruption of 
the retina, early detection of CNV is desirable; indeed, detection of CNV before retinal 
invasion would be ideal. CNV that has breached the retina can be detected by fluorescein 
angiography. However, this diagnostic modality cannot detect CNV before it has invaded 
the retina, i.e., when it is still limited to the choroid. Yet postmortem histopathological 
studies have shown that substantial numbers of patients in whom fluorescein angiography 
does not reveal the presence of CNV nevertheless have CNV that has not yet invaded the 
retina31. Therefore, we explored whether CCR3-targeted bioimaging using anti-CCR3 Fab 
antibody fragments (Supplementary Fig. S7) conjugated to quantum dots (QDot-CCR3 Fab) 
could detect CNV before it became clinically evident.
We previously described the spontaneous development of CNV in senescent mice deficient 
in monocyte chemoattractant protein-1 (MCP-1/CCL-2) or its CCR2 receptor32. Similar 
pathology occurs at a younger age in Ccl2−/− × Ccr2−/− mice (unpublished data). These mice 
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also undergo outer retinal degeneration rapidly (Supplementary Fig. S8). We tested whether 
fundus angiography following intravenous injection of QDot-CCR3 Fab could detect 
subretinal CNV in these mice. QDot-CCR3 Fab angiography demonstrated hyperfluorescent 
signals in regions of the fundus of these mice that were silent on fluorescein angiography 
(Fig. 4a,b). The specificity of CCR3 targeting was confirmed by the absence of 
hyperfluorescent signals in Ccl2−/− × Ccr2−/− mice injected with QDot-isotype Fab and in 
wild-type mice injected with QDot-CCR3 Fab (Fig. 4b; Supplementary Fig. S9). 
Histological examination of these areas revealed proliferating (Ki67+) CCR3+ blood vessels 
in the choroid that had not yet invaded the retina, along with accumulation of QDot-CCR3 
Fab in these vessels (Fig. 4c-e). These data provide proof of principle that CCR3-targeted 
bioimaging can detect subclinical CNV before it disrupts the retina and causes vision loss.
CCR3 targeting superior to VEGF-A targeting
In comparing CCR3 targeting to VEGF-A targeting, the most effective approved treatment 
for human CNV, we found that CCR3 neutralizing antibodies were more effective than 
VEGF-A neutralizing antibodies (68±3% vs. 57±4%) at inhibiting laser-induced CNV in 
mice (Supplementary Fig. S10). In the laser injury model, CCR3 neutralization did not 
change VEGF-A levels in the RPE/choroid and VEGF-A blockade did not change CCR3 
expression on CECs (Supplementary Fig. S11): these two pathways appear to be not directly 
coupled. Repeated intravitreous administration of anti-VEGF-A antibodies resulted in 
anatomic and functional damage to the retina in wild-type mice (Supplementary Fig. S12), 
consistent with earlier reports that anti-VEGF-A therapy induces dysfunction in and damage 
to the inner and outer murine retina6,7. These effects were modest at a dose of anti-VEGF-A 
antibodies that suppressed mouse CNV but more pronounced at a higher dose that is 
comparable to the dose used in humans. It should be noted that anti-VEGF-A 
pharmacotherapy has not been associated with an increased risk of profound retinal damage 
in humans33, but subtle abnormalities have been observed34,35 and some adverse effects 
might be misattributed to disease progression. In contrast to VEGF-A blockade, neither 
CCR3 Ab nor CCR3 receptor antagonist induced retinal toxicity in wild-type mice as 
confirmed by fundus imaging and electrophysiological function (Supplementary Fig. S12). 
Vegfa deletion is embryonically lethal36,37 and conditional ablation of Vegfa in the RPE 
induces profound retinal degeneration and visual dysfunction38. In contrast, the Ccr3−/− 
mouse retina was normal in appearance and electrophysiological function (Supplementary 
Fig. S13).
Discussion
Our findings suggest that CCR3 targeting may be a safe and viable strategy for early 
detection (using biocompatible quantum dots or other bioimaging fluorochromes such as 
near infrared dyes) and treatment of CNV (by receptor or ligand targeting) that might be 
superior to current standard of care. CCR3 bioimaging is likely to be most useful in 
individuals with RPE pigmentary disturbances and multiple subretinal lipoproteinaceous 
deposits known as drusen or fellow eye involvement with clinically evident CNV, as they 
are known to be at high risk for developing CNV39,40. Similar techniques might be useful 
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in non-invasively bioimaging other metabolic or molecular markers to provide information 
about disease pathogenesis or activity.
Several strategies have yielded molecular markers that are preferentially expressed on 
proliferating endothelial cells such as those in tumour vasculature41,42; however, CCR3 has 
not been identified in any of these reports. Therefore, our studies identify CCR3 as a novel 
marker of pathological angiogenesis and as a functional target in neovascular AMD. These 
findings also should prompt a search for genetic polymorphisms in the eotaxin-CCR3 axis in 
patients with AMD, and investigations of CCR3 function in other models of angiogenesis. 
Also, it is tempting to speculate that targeting CCR3 might provide dual benefits in asthma, 
which involves varying degrees of eosinophilic inflammation as well as angiogenic airway 
remodelling43.
Methods Summary
Mouse model of CNV
Laser photocoagulation (OcuLight GL, Iridex Corporation) was performed on mouse eyes to 
induce CNV, and CNV volumes were measured 7 days after injury by scanning laser 
confocal microscope (TCS SP, Leica) as previously described22.
Drug injections
Rat IgG2a neutralizing antibody against mouse CCR3 (R&D Systems), control rat IgG2a 
(Serotec), goat neutralizing antibody against mouse CCL11 (R&D Systems), goat 
neutralizing antibody against mouse CCL24 (R&D Systems), control goat IgG (Jackson 
Immunoresearch), or (S)-Methyl-2-naphthoylamino-3-(4-nitrophenyl)propionate 
(SB328437; Calbiochem) dissolved in DMSO were injected into the vitreous humor using a 
33-gauge double-calibre needle (Ito Corporation) once, immediately after laser injury as 
previously described22.
CCR3 bioimaging
F(ab) fragments were created from monoclonal IgG2a antibody raised against the 
extracellular domain of murine CCR3 (R&D Systems) and an isotype rat IgG2a (R&D 
Systems) using a commercially available papain-based kit (Pierce). Recovered fragments 
were conjugated with quantum dots (Invitrogen, QDot-800) and resuspended in sterile PBS. 
Ccl2−/− × Ccr2−/− mice were administered 100 μg of tagged CCR3 F(ab) or isotype F(ab) 
via tail vein injection after acquiring baseline fluorescent imaging using a Topcon retinal 
camera (TRC-50IX). Serial images were then acquired at 1, 4, and 12 h after which eyes 
were harvested and frozen in OCT for immunofluorescent analyses. Retinal images were 
analyzed (ImageNet, Topcon) by comparison to baseline and fluorescein angiographic data. 
Hyperfluorescent areas were then cropped, equally thresholded, and pseudocoloured 
(Photoshop CS3, Adobe). Sections from QDot-conjugated CCR3 or rat IgG2a isotype F(ab) 
injected animals were fixed in 4% paraformaldehyde and blocked with 5% normal donkey 
serum/5% goat serum in PBS, stained with rat anti-mouse CD31 (BD Biosciences) and 
either rabbit anti-mouse CCR3 (Santa Cruz) or rabbit anti-Ki67 (Abcam) followed by 
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appropriate fluorescent secondary antibodies (Alexa Fluor 488/594, Invitrogen), and 
evaluated by confocal laser scanning microscopy (Leica SP-5).
Methods
Human tissue
Choroidal neovascularization (CNV) tissue was excised from patients with age-related 
macular degeneration (AMD) who had no prior treatment for CNV. Retinal fibrosis tissue 
was excised from patients with a diagnosis of epiretinal membrane formation. Donor eyes 
from patients with atrophic AMD without CNV and patients without AMD were obtained 
from eye banks. Eyes with choroidal melanoma were obtained by surgical enucleation. The 
study followed the guidelines of the Declaration of Helsinki. Institutional review boards 
granted approval for allocation and histological analysis of specimens.
Animals
All animal experiments were in accordance with the guidelines of the University of 
Kentucky IACUC and the Association for Research in Vision and Ophthalmology. 
C57BL/6J and KitW-v/KitW-v mice were purchased from The Jackson Laboratory. Ccr3−/−, 
Ccl11−/−, Ccl24−/−, Ccl11−/− × Ccl24−/−, and Δdbl GATA mice have been previously 
described11,12,25,26. Ccl2−/− × Ccr2−/− mice were generated by interbreeding “single 
knockout” mice described previously32.
Drug injections
Rat IgG2a neutralizing antibody against mouse CCR3 (R&D Systems), control rat IgG2a 
(Serotec), goat neutralizing antibody against mouse CCL11 (1 μg; R&D Systems), goat 
neutralizing antibody against mouse CCL24 (5 μg; R&D Systems), control goat IgG 
(Jackson Immunoresearch), or (S)-Methyl-2-naphthoylamino-3-(4-nitrophenyl)propionate 
(SB328437; Calbiochem) dissolved in DMSO were injected into the vitreous humor of mice 
using a 33-gauge double-calibre needle (Ito Corporation) once, immediately after laser 
injury as previously described22.
Flow cytometry
Rat antibody against mouse CCR3 (1:250; Santa Cruz) coupled with PE-donkey antibody 
against rat IgG (1:250; Jackson Immunoresearch) or AlexaFluor647-conjugated rat antibody 
against mouse CCR3 (10 μg/ml; BD Biosciences) were used to quantify cell surface receptor 
expression on choroidal endothelial cells, defined by CD31+ VEGFR-2+ expression, gated 
by FITC-conjugated rat antibody against mouse CD31 (20 μg/ml; BD Biosciences) and PE-
conjugated rat antibody against mouse VEGFR-2 (20 μg/ml; BD Biosciences). 
Macrophages, neutrophils, eosinophils and mast cells were defined as F4/80+CD11c−, 
Gr-1+F4/80−, CCR3hiCD3−CD117intCD49d+ and CCR3intCD3− CD117hiCD49d+ cells, 
respectively. DNA content for cell cycle was analyzed after incubation with propidium 
iodide (0.05 mg/ml; Molecular Probes) containing 0.1% Triton X-100 and RNase A (0.1 
mg/ml; Roche). Samples were analyzed on a LSRII (Becton Dickinson).
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Immunofluorescent staining was performed with antibodies against human CCR3 (rat 
monoclonal, R&D Systems) or human CD31 (mouse monoclonal, Dako) and identified with 
Alexa 488 (Molecular Probes) or Cy3 secondary antibodies (Jackson ImmunoResearch). 
Immunohistochemical staining with the primary antibodies specific for human eotaxins-1, 2 
and 3 (mouse monoclonal, R&D Systems) was performed using horseradish peroxidase. 
Laser injured mouse eye sections were stained with antibodies against mouse CCL11 or 
CCL24 (both R&D Systems) along with antibody against mouse CD31 (BD Biosciences) 
and visualized with FITC or Cy3 secondary antibodies. Images were obtained using Leica 
SP5 or Zeiss Axio Observer Z1 microscopes.
Tube formation assay
96-well plates were coated with Growth Factor Reduced Matrigel (BD Biosciences) mixed 
with rat neutralizing antibody against human CCR3 (20 μg/ml, R&D Systems) or control rat 
IgG2a (Invitrogen) and allowed to solidify in the incubator at 37 °C for 45 min. Human 
choroidal endothelial cells (CECs)44-47 were plated on top of the Matrigel at 2.25 × 
104/cm2 in EBM-2 basal media (Cambrex) containing 1% FBS with CCR3 antibody or rat 
IgG2a at the above concentrations and allowed to grow overnight. Tube formation was 
analyzed by counting the number of cell junctions per mm2.
Proliferation assay
Human CECs were synchronized for cell cycle state by first cultivating them in EGM2-MV 
media (Lonza) supplemented with 10% FBS (Gibco) to achieve complete confluence and 
then by overnight serum starvation in MCDB131 media (Gibco) with 0.1% FBS. They were 
passaged to 96-well plates at a density of 5,000 cells per well, followed by stimulation for 
24 h with eotaxin-1, 2 or 3 (10 ng, 100 ng and 2 μg per ml, respectively; Peprotech) in 
MCDB131 media with 0.1% FBS. After 24 h, cell viability was measured with BrdU ELISA 
(Chemicon) according to manufacturer's instructions.
F-actin Polymerization Assay
Human CECs were seeded in black-walled 96-well plates and grown to 70-80% confluence 
in fully supplemented EGM-2MV. Cultures were serum starved overnight in basal media 
and then stimulated with recombinant human eotaxin-1 (10 ng/ml), eotaxin-2 (100 ng/ml), 
eotaxin-3 (2 μg/ml) (Peprotech), or vehicle control (PBS). At 0, 10, 30, 60, or 120 sec time-
points, cells were fixed in 3.7% paraformaldehyde for 10 min, washed, permeabilized in 
PBS with 0.1% Triton-X, and then stained with rhodamine labelled Phalloidin (1:200, 
Invitrogen) per manufacturer's recommendations. Plates were analyzed on a fluorescent 
plate reader (Synergy 4, Biotek) followed by fluorescent microscopy (Nikon E800).
Migration Assay
Eotaxins-1, -2, -3 were reconstituted in 0.1% bovine serum albumin (BSA) and then mixed 
with Matrigel diluted 1:1 with serum free endothelial basal media (EBM-2; Lanza). 500 μl 
of EBM-2 was added to each well of a 24-well plate followed by a 6.5 mm diameter 
Transwell insert (8 μm pores; Corning). Human CECs in EBM-2 were prestained with 
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Vybrant DiO (Invitrogen) for 30 min at 37 °C and seeded into the inserts at 50,000 cells per 
200 μl of serum free EBM-2 media. The plates were allowed to incubate for 16 h at 37 °C, 
5% CO2. The migrated cells were imaged with an Olympus CK40 microscope and Olympus 
DP71 camera.
Rac-1 activation
Human CECs were cultured in EGM-2 MV containing 5% FBS. Prior to starting the assay, 
cells were serum starved with basal medium (MCDB131) supplemented with 1% FBS 
overnight. Cells were stimulated for designated times with Eotaxin-1, 2 and 3 (10 ng/ml, 100 
ng/ml and 2 μg/ml respectively). Equal amounts of lysates (500 μg) were incubated with 
GST-Pak1-PBD agarose beads (Upstate) to pull-down active GTP-bound Rac-1 at 4 °C for 1 
h with rotation. The samples were subsequently analyzed for bound Rac-1 by western blot 
analysis using an anti-Rac-1 antibody (Upstate).
Electroretinography
Mice were dark adapted overnight and then anesthetized. Both eyes were positioned within a 
ColorBurst Ganzfeld stimulator (Diagnosys). Espion software (Diagnosys) was used to 
program a fully automated flash intensity series from which retinal responses were recorded.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CCR3 and eotaxins are expressed in choroidal neovascularization. a,b, Immunofluorescence 
shows that CCR3 (green) receptor expression colocalizes with CD31+ (red) expressing 
blood vessels in surgically excised human age-related macular degeneration (AMD) 
choroidal neovascular (CNV) tissue. Nuclei stained blue by DAPI. b, Specificity of CCR3 
staining is confirmed by absence of staining with isotype control IgG (a). Individual red and 
green fluorescence channels are shown in Supplementary Fig. S1. c,d, CCR3 is not 
immunolocalized in CD31+ (red) blood vessels (white arrowheads) in the choroid of patients 
with atrophic AMD who do not have CNV (c) or in aged patients without AMD (d). 
Autofluorescence of retinal pigmented epithelium (white arrow) and Bruch's membrane 
(asterisks) overlying choroid is seen (c,d). e,f, CCR3 is not expressed in surgically excised 
avascular retinal fibrosis tissue (e) or in blood vessel of choroidal melanoma (f). g-j, 
Immunohistochemistry (golden brown reaction product) shows expression of CCL11 (g), 
CCL24 (h), and CCL26 (i) in surgically excised AMD CNV tissue, primarily in the stroma 
(red arrowheads) but also in the blood vessels (yellow arrows). Specificity of staining is 
confirmed by absence of staining with isotype control IgG (j). Scale bars, 10 μm.
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CCR3 activation promotes angiogenesis. a, Tube formation of primary human choroidal 
endothelial cells (CECs) in Matrigel in vitro was reduced by neutralizing anti-human CCR3 
antibodies (Ab) compared to isotype IgG. n = 6, * P < 0.05 compared to isotype IgG. b, 
Fraction of CD31+VEGFR2+ gated mouse CECs in vivo in proliferative state (S phase) was 
increased 5 days after laser injury in wild-type mouse eyes compared to control (uninjured 
eyes), and was reduced by intraocular administration of neutralizing anti-mouse CCR3 Ab 
compared to isotype IgG. n = 6–10, * P < 0.05 compared to IgG treatment. c, Stimulation 
with eotaxins for 24 h induced human CEC proliferation. n = 4, * P < 0.05 compared to 
bovine serum albumin (BSA) treatment. d,e, Stimulation with eotaxins, but not PBS, 
induced actin polymerization in human CECs. Relative F-actin content is expressed as the 
ratio of the mean channel fluorescence between eotaxin- and media alone-stimulated cells 
(d). Rhodamine-phalloidin staining (red) shows F-actin fibre formation in eotaxin-
stimulated cells (e). Nuclei stained blue by DAPI. Data representative of 3–4 independent 
experiments are shown. c,e, CCL11 (10 ng/ml), CCL24 (100 ng/ml), CCL26 (2 μg/ml). f, 
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Stimulation with eotaxins for 16 hours induces dose-dependent migration of human CECs 
across 8 μm pore size Transwells. n = 5–10, * P < 0.05 compared to BSA treatment. (a–c, f) 
Significance by Mann-Whitney U test. Error bars depict s.e.m.
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CNV reduced by CCR3 or eotaxin ablation or blockade independent of leukocyte 
modulation. a,b, Laser-induced CNV in wild-type mice was reduced by neutralizing anti-
mouse CCR3 Ab compared to isotype IgG (a) and by the CCR3 receptor antagonist (RA) 
SB328437 ((S)-Methyl-2-naphthoylamino-3-(4-nitrophenyl)propionate) compared to vehicle 
(PBS/DMSO) (b) in a dose-dependent fashion. n = 8–12, * P < 0.05 compared to no 
antibody or receptor antagonist. c, Representative examples of CNV in drug-treated mice. d, 
Laser-induced CNV was reduced in Ccr3−/− mice compared to wild-type mice. n = 9, * P < 
0.05 compared to wild-type mice. e, Eotaxin-1 (Ccl-11) and eotaxin-2 (Ccl-24) protein 
levels, measured by ELISA, were increased following laser injury in wild-type mice. n = 6, 
* P < 0.05, # P < 0.01 compared to 0 h baseline. f, Ccl-11 and Ccl-24 immunofluorescence 
(green) was localized in the retinal pigmented epithelial cell layer (arrows) adjacent to 
CD31+ (red) choroidal endothelial cells (arrowheads) on day 1 after laser injury in wild-type 
mice. Nuclei stained blue by DAPI. No specific immunofluorescence was detected with 
isotype control IgGs. Images representative of 3 independent experiments are shown. g, 
Laser-induced CNV was reduced in Ccl11−/− and in Ccl24−/− mice compared to wild-type 
mice. n = 8–10, * P < 0.05 compared to wild-type mice. CNV is further reduced in Ccl11−/− 
× Ccl24−/− mice compared to single null mice. # P < 0.05 compared to single null mice. h, 
Laser-induced CNV in wild-type mice was reduced by neutralizing antibodies against mouse 
CCL11 or CCL24 compared to isotype IgG. n = 7–10, * P < 0.05 compared to no injection 
(control) or IgG. i, Representative examples of CNV in eotaxin-neutralized mice. j, 
Neutralizing anti-CCR3 antibodies (Ab) reduced laser-induced CNV in mice deficient in 
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eosinophils (Δdbl GATA) or mast cells (Kitw-v). n = 6–9, * P < 0.05 compared to IgG. Scale 
bars, (c,i), 100 μm; f, 20 μm. Error bars depict s.e.m.
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CCR3-targeting quantum dots detect subretinal choroidal neovascularization (CNV). a, 
Images of the fundus taken after intravenous injection of sodium fluorescein in wild-type 
and Ccl2−/− × Ccr2−/− mice showed normal retinal vascular filling but no areas of 
hyperfluorescence indicative of CNV. b, After intravenous injection of QDot-CCR3 Fab in 
the same Ccl2−/− × Ccr2−/− mouse shown in (a), focal branching choroidal 
hyperfluorescence was visualized (arrow) at 1 h in the same area that was not 
hyperfluorescent during fluorescein angiography (arrowhead in a). The intensity of this 
hyperfluorescence (shown in red pseudocolour in the inset) increased, attaining a peak at 4 
h, and then declined in intensity but still persisted at 12 h. Corresponding images of QDot-
Isotype Fab angiography showed no hyperfluorescence. c–e, The region corresponding to 
the area of hyperfluorescence seen on QDot-CCR3 Fab angiography in (b) contained 
multiple CD31+ blood vessels in the choroid (Ch) that were proliferating (Ki67+; arrows) 
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and had not invaded the retina (Ret). Individual red (CD31+, c), and green (Ki67+, d), and 
merged (e) fluorescence channel images are shown. Arrows point to proliferating 
endothelial cells. Inset shows Ki67+ CD31+ cells in higher magnification. f, QDot-CCR3 
Fab hyperfluorescent areas were localized to areas of subretinal CNV with CCR3+ 
endothelial cells. g, The QDot label was visualized within CD31+ vasculature of subretinal 
CNV lesions. Images representative of 6 independent experiments. Scale bars, (c–e), 10 μm.
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